Innovair (Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous)

Beclometasone dipropionate binds to glucocorticoid receptors in airway cells, suppressing inflammatory mediators and decreasing swelling. Formoterol fumarate stimulates β2‑adrenergic receptors on bronchial smooth muscle, raising cyclic AMP levels and causing prolonged bronchodilation. Together they address both the inflammatory and bronchoconstrictive components of asthma and COPD.

The dose of Innovair is individualized by the prescribing healthcare professional based on disease severity, age, and response to therapy. The prescriber determines the number of inhalations per day and the total daily dose, which should be followed exactly as instructed on the prescription label.

Safety data for Innovair in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare provider.

To order Innovair, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Innovair combines a corticosteroid (beclometasone) with a long‑acting β2‑agonist (formoterol) in a single metered‑dose inhaler, offering convenience over separate inhalers. Compared with products that contain only a steroid or only a bronchodilator, Innovair provides dual action, which can improve adherence and simplify regimens. Its efficacy is comparable to other combination inhalers such as fluticasone/salmeterol, but individual response may vary.

Innovair should be stored at room temperature, below 25 °C (77 °F). Keep the inhaler in its original packaging, protect it from moisture and direct heat, and avoid exposing it to freezing temperatures. Do not puncture or tamper with the canister, and replace the inhaler after the indicated number of doses has been used.

Innovair is delivered via a metered‑dose inhaler (MDI). The patient should shake the inhaler well, exhale fully, place the mouthpiece in the mouth, and press down on the canister while inhaling slowly and deeply. Hold the breath for about 10 seconds, then exhale slowly. The inhaler should be rinsed with water after use to reduce the risk of oral thrush.

Serious adverse events, although uncommon, include paradoxical bronchospasm (sudden worsening of breathing), adrenal suppression, severe allergic reactions such as anaphylaxis, pneumonia (particularly in COPD patients), and cardiac arrhythmias or tachycardia. Patients should seek immediate medical attention if they experience sudden breathlessness, swelling, rash, or irregular heartbeats.

Innovair is contraindicated in individuals with a known hypersensitivity to beclometasone, formoterol, or any component of the inhaler. It should also be avoided in patients who have experienced a severe paradoxical bronchospasm with a β2‑agonist. Caution is advised for patients with uncontrolled cardiovascular disease, severe hypertension, or hyperthyroidism, and the drug should be used only under medical supervision in these cases.